<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2467">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327505</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-19-HBO</org_study_id>
    <secondary_id>2020-001349-37</secondary_id>
    <secondary_id>K-1199/2020</secondary_id>
    <nct_id>NCT04327505</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19</brief_title>
  <acronym>COVID-19-HBO</acronym>
  <official_title>A Randomized, Controlled, Open Label, Multicentre Clinical Trial to Explore Safety and Efficacy of Hyperbaric Oxygen for Preventing ICU Admission, Morbidity and Mortality in Adult Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Trial Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blekinge County Council Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>JK Biostatistics AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 may cause severe pneumonitis that require ventilatory support in some patients, the
      ICU mortality is as high as 62%. Hospitals do not have enough ICU beds to handle the demand
      and to date there is no effective cure.

      We explore a treatment administered in a randomized clinical trial that could prevent ICU
      admission and reduce mortality.

      The overall hypothesis to be evaluated is that HBO reduce mortality, increase hypoxia
      tolerance and prevent organ failure in patients with COVID19 pneumonitis by attenuating the
      inflammatory response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective: To evaluate if HBO reduce the number of ICU admissions compared to Best
      practice for COVID-19

      Secondary objectives:

      Main secondary objectives:

      To evaluate if HBO:

        -  reduces mortality in severe cases of COVID-19.

        -  reduces morbidity associated with COVID-19.

        -  reduce the load on ICU resources in COVID-19.

        -  mitigate the inflammatory reaction in COVID-19.

      Other secondary objectives (in selection):

      To evaluate if HBO is safe for SARS-CoV-2 positive patients and staff.

      Study design: Randomized, controlled, phase II, open label, multicentre

      Study population: Adult patients with SARS-CoV-2 infection, with at least two risk factor for
      increased mortality, likely to develop ARDS criteria and need intubation within 7 days of
      admission to hospital.

      Number of subjects: 200 (20+180)

      Investigational product: Hyperbaric oxygen (HBO) compared with best practice treatment HBO:
      HBO 1.6-2.4 ATA for 30-60 min, maximum 5 treatments first 7 days Control: Best practice
      treatment for COVID-19
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled, open label, multi-centre clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICU admission</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>The proportion of subjects admitted to ICU from day 1 to day 30, based on at least one of the following criteria:
i) Rapid progression over hours ii) Lack of improvement on high flow oxygen &gt;40L/min or non invasive ventilation with fraction of inspired oxygen (FiO2) &gt; 0.6 iii) Evolving Hypercapnia or increased work of breathing not responding to increased oxygen despite maximum standard of care available outside ICU iv) Hemodynamic instability or multi organ failure with maximum standard of care available outside ICU</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Proportion of subjects with 30-day mortality, all cause Mortality, from day 1 to day 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-intubation</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Time-to-Intubation, i.e. cumulative days free of invasive mechanical ventilation, from day 1 to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-ICU</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Time-to-ICU, i.e. cumulative ICU free days, derived as the number of days from day 1 to ICU, where all ICU free subjects are censored at day 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory response</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Mean change in inflammatory response from day 1 to day 30.
White cell count + differentiation
Procalcitonin
C-Reactive protein
Cytokines (IL-6) (if available at local laboratory)
Ferritin
D-Dimer
LDH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Overall survival (Kaplan-Meier)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Hospital mortality of any cause, proportion of subjects, from day 1 to day 30.</description>
  </other_outcome>
  <other_outcome>
    <measure>ICU mortality</measure>
    <time_frame>From ICU admission to study completion 30 days</time_frame>
    <description>Proportion of subjects with ICU mortality, Mortality of any cause in ICU, from day 1 to day 30.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time in Invasive Ventilation</measure>
    <time_frame>From ICU admission to study completion 30 days</time_frame>
    <description>Time-to-stop of intubation/invasive mechanical ventilation, from ICU admission to day 30.</description>
  </other_outcome>
  <other_outcome>
    <measure>NEWS</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Mean daily NEWS from day 1 to day 30.</description>
  </other_outcome>
  <other_outcome>
    <measure>PaO2/FiO2 (PFI)</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Mean change in PaO2/FiO2 (PFI), from day 1 to day 2, â€¦ to day 30.</description>
  </other_outcome>
  <other_outcome>
    <measure>HBO Compliance</measure>
    <time_frame>Day 1 to day 7</time_frame>
    <description>Proportion of HBO treatments given vs planned.
Proportion of subjects with HBO treatment administered within 24h after enrolment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital discharge</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Time-to-discharge from hospital</description>
  </other_outcome>
  <other_outcome>
    <measure>Oxygen dose</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Mean oxygen dose per day including HBO and cumulative pulmonary oxygen toxicity expressed as Units of oxygen pulmonary toxicity dose (UPTD) and Cumulative pulmonary toxicity dose (CPTD) from day 1 to day 30.</description>
  </other_outcome>
  <other_outcome>
    <measure>HBO dose</measure>
    <time_frame>Day 1 to day 7</time_frame>
    <description>Median number of HBO treatments and dose of HBO given, from day 1 to day 7</description>
  </other_outcome>
  <other_outcome>
    <measure>Micro RNA</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Change in expression of Micro RNA in plasma from day 1 to day 30</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypoxic response</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Change in gene expression and Micro RNA interactions in Peripheral Blood Mononuclear Cells (PBMC) (20 Subjects) from day 1 to day 30</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunological response</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Immunological response (20 subjects) from day 1 to day 30 in the following.
Cytokines extended including (IL-1Î², IL-2, IL-6, IL33 and TNFÎ±)
Lymphocyte profile
Flowcytometry with identification of monocyte/lymphocyte subsets including but not limited to CD3+/CD4+/CD8+ and CD4+/CD8+ ratio
FITMaN panel/Flow cytometry, Interleukins (IL-1Î², IL-2, IL-6, IL33 and TNFÎ±),
T-reg cells (CD3+/CD4+/CD25+/CD127+)
Monocyte proliferation markers, Ex vivo monocyte function</description>
  </other_outcome>
  <other_outcome>
    <measure>Multi organ dysfunction</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Mean change in routine biomarkers for organ dysfunction, from day 1to day 30.</description>
  </other_outcome>
  <other_outcome>
    <measure>Viral load</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Viral load, review of records from day 1 to day 30.</description>
  </other_outcome>
  <other_outcome>
    <measure>Secondary infections</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Number of secondary infections, review of records, number of events and patients from day 1 to day 30.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary embolism</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Diagnosed PE needing treatment, review of records, number of events and patients from day 1 to day 30.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary CT</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Changes on Pulmonary CT, review of records from day 1 to day 30.</description>
  </other_outcome>
  <other_outcome>
    <measure>Chest X-ray</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Changes on Chest X-ray, review of records from day 1 to day 30.</description>
  </other_outcome>
  <other_outcome>
    <measure>Lung ultrasound</measure>
    <time_frame>Through study completion 30 days</time_frame>
    <description>Changes in Lung ultrasound, review of records from day 1 to day 30.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
  <condition>Cytokine Storm</condition>
  <condition>ARDS, Human</condition>
  <condition>COVID-19</condition>
  <condition>Sars-CoV2</condition>
  <condition>Acute Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric oxygen 1,6-2.4 Bar for 30-60 minutes (compression/decompression time, according to local routines) in addition to best practice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Best practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen</intervention_name>
    <description>1.6- 2.4 ATA, 30-60 min (excluding compression/recompression)</description>
    <arm_group_label>Hyperbaric oxygen</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Aged 18-90 years

          2. PaO2/FiO2 (PFI) below 200 mmHg (26.7 kPa)

          3. Suspected or verified SARS-CoV-2 infection

          4. At least two risk factors for increased morbidity/mortality

               -  Age above 50 years

               -  Hypertension

               -  Cardiovascular disease

               -  Diabetes or pre-diabetes

               -  Active or cured cancer

               -  Asthma/COPD

               -  Smoking

               -  D-Dimer &gt; 1.0

               -  Auto-immune disease

          5. Documented informed consent according to ICH-GCP and national regulations

        Exclusion Criteria:

          1. ARDS/pneumonia caused by other viral infections (positive for other virus)

          2. ARDS/pneumonia caused by other non-viral infections or trauma

          3. Known pregnancy or positive pregnancy test in women of childbearing age

          4. Patients with previous lung fibrosis more than 10%

          5. CT- or Spirometry-verified severe COPD with Emphysema

          6. Contraindication for HBO according to local guidelines

          7. Not likely to need ICU admission &lt; 7 days of screening (Subjective criteria that may
             exclude any patients that fulfil the other inclusion criteria but where the treating
             physician suspect a spontaneous recovery)

          8. Mental inability, reluctance or language difficulties that result in difficulty
             understanding the meaning of study participation

          9. Prisoner (Exclusion criteria according to IRB at UCSD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Adults, all genders</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Kjellberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Lindholm, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenny Rodriguez-Wallberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders Kjellberg, MD</last_name>
    <phone>+46812375212</phone>
    <email>anders.kjellberg@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Lindholm, MD, PhD</last_name>
    <phone>+16508230735</phone>
    <email>plindholm@health.ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bergmannsheil und Kinderklinik Buer GmbH</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>45894</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georg Rinneberg</last_name>
      <phone>+4916093954430</phone>
      <email>georg.rinneberg@bergmannsheil-buer.de</email>
    </contact>
    <investigator>
      <last_name>Michael Kraus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Joesf</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Pawlik, MD, PhD</last_name>
      <phone>+499417823610</phone>
      <email>mpawlik@caritasstjosef.de</email>
    </contact>
    <investigator>
      <last_name>Michael Pawlik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blekingesjukhuset</name>
      <address>
        <city>Karlskrona</city>
        <state>Blekinge</state>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Douglas, MD</last_name>
      <phone>+46708123223</phone>
      <email>j@douglas.nu</email>
    </contact>
    <investigator>
      <last_name>Johan Douglas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://www.uhms.org/covid-19-information.html</url>
    <description>UHMS position statement and information on HBO for COVID-19</description>
  </link>
  <link>
    <url>https://ki.se/en/fyfa/hyperbaric-medicine</url>
    <description>Hyperbaric medicine research group, Karolinska Institutet</description>
  </link>
  <link>
    <url>http://www.eubs.org/?p=1074</url>
    <description>COVID-19 EUBS-ECHM position statement on HBOT</description>
  </link>
  <link>
    <url>https://news.ki.se/ki-researchers-to-evaluate-effect-of-hyperbaric-oxygen-treatment-against-covid-19</url>
    <description>KI News-description of trial in layman language</description>
  </link>
  <reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </reference>
  <reference>
    <citation>Oscarsson N, MÃ¼ller B, RosÃ©n A, Lodding P, MÃ¶lne J, Giglio D, Hjelle KM, VaagbÃ¸ G, Hyldegaard O, Vangedal M, Salling L, Kjellberg A, Lind F, Ettala O, Arola O, Seeman-Lodding H. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. Lancet Oncol. 2019 Nov;20(11):1602-1614. doi: 10.1016/S1470-2045(19)30494-2. Epub 2019 Sep 16. Erratum in: Lancet Oncol. 2019 Sep 23;:.</citation>
    <PMID>31537473</PMID>
  </reference>
  <reference>
    <citation>Thibodeaux K, Speyrer M, Raza A, Yaakov R, Serena TE. Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series. J Wound Care. 2020 May 1;29(Sup5a):S4-S8. doi: 10.12968/jowc.2020.29.Sup5a.S4.</citation>
    <PMID>32412891</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Anders Kjellberg, MD</investigator_full_name>
    <investigator_title>ICU Consultant/PhD student</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Hyperbaric oxygen</keyword>
  <keyword>ARDS</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>ICU admission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

